<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="44423">Hydroxyurea</z:chebi> therapy reduces <z:mp ids='MP_0010163'>hemolysis</z:mp> and decreases serum <z:chebi fb="0" ids="16990">bilirubin</z:chebi> levels in children and adults with sickle cell <z:hpo ids='HP_0001903'>anemia</z:hpo> (SCA) and may therefore help prevent the development of <z:hpo ids='HP_0001081'>cholelithiasis</z:hpo> in this patient population </plain></SENT>
<SENT sid="1" pm="."><plain>We recently reported that a promoter polymorphism in the <z:chebi fb="0" ids="16704">uridine</z:chebi> diphosphoglucuronate glucuronosyltransferase 1A (UGT1A) gene affects steady-state <z:chebi fb="0" ids="16990">bilirubin</z:chebi> levels and the incidence of <z:hpo ids='HP_0001081'>gallstones</z:hpo> in children with SCA </plain></SENT>
<SENT sid="2" pm="."><plain>We have now analyzed the influence of the UGT1A genotype on the therapeutic response to <z:chebi fb="0" ids="44423">hydroxyurea</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>A large cohort of children with SCA taking <z:chebi fb="0" ids="44423">hydroxyurea</z:chebi> therapy at the maximum tolerated dose demonstrated significant reductions in <z:mp ids='MP_0010163'>hemolysis</z:mp> independent of UGT1A promoter polymorphism genotype, but the <z:chebi fb="0" ids="44423">hydroxyurea</z:chebi>-related decreases in serum <z:chebi fb="0" ids="16990">bilirubin</z:chebi> levels were significantly different </plain></SENT>
<SENT sid="4" pm="."><plain>Children with the <z:mp ids='MP_0002169'>wild-type</z:mp> 6/6 UGT1A genotype demonstrated normalized <z:chebi fb="0" ids="16990">bilirubin</z:chebi> levels with <z:chebi fb="0" ids="44423">hydroxyurea</z:chebi> therapy, but children with the heterozygous 6/7 or abnormal 7/7 genotypes did not </plain></SENT>
<SENT sid="5" pm="."><plain>Children with the abnormal 7/7 genotype, which confers the phenotype of <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert syndrome</z:e>, had <z:chebi fb="0" ids="16990">bilirubin</z:chebi> levels greater than 3 mg/dL despite full-dose <z:chebi fb="0" ids="44423">hydroxyurea</z:chebi> therapy </plain></SENT>
<SENT sid="6" pm="."><plain>These data indicate the UGT1A promoter polymorphism is a powerful nonglobin genetic modifier in SCA that influences serum <z:chebi fb="0" ids="16990">bilirubin</z:chebi> both at baseline and on <z:chebi fb="0" ids="44423">hydroxyurea</z:chebi> therapy </plain></SENT>
<SENT sid="7" pm="."><plain>UGT1A promoter polymorphisms may therefore influence the ability of <z:chebi fb="0" ids="44423">hydroxyurea</z:chebi> to prevent <z:mp ids='MP_0002830'>gallstone</z:mp> formation in patients with SCA </plain></SENT>
</text></document>